ArticleBiomedical engineering and computational biology2026
Mechanistic Elucidation of Liujun Jiaoxian Tang in Management of Sepsis Through Metabolomics and Network Pharmacology.
Article in Biomedical engineering and computational biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study was aimed to investigate the blood composition and potential mechanism of Liujun Jiaoxian Tang (LJJXT) for treating sepsis. Methods: After drug intervention in rats, the main active components in LJJXT liquid and serum were identified by UPLC-QE-MS analysis. The effective components and their targets of LJJXT were further screened through the TCMSP database; the disease-related action targets were retrieved by using the Disgenet and Genecards databases. The intersection of the two sets of targets was taken to construct the "LJJXT-components-targets-diseases" network, PPI diagram, GO and KEGG enrichment analysis diagram. Subsequently, molecular docking studies were conducted on the key targets for treating diseases screened by PPI and the corresponding effective components in LJJXT. Results: There were 2159 active ingredients in LJJXT, of which 90 were effective in blood. The 20 screened active ingredients matched 139 targets. There were a total of 2585 disease-related targets, and 76 targets shared by drugs and diseases. There were 2113 biological processes, 43 cell components, 211 molecular functions in GO analysis and 172 pathways obtained by KEGG analysis. The results showed that LJJXT may act on AKT1, TNF, PTGS2 and other targets through the active ingredients in blood such as terpenoids, flavonoids, phenols and alkaloids. It was involved in the regulation of lipid and atherosclerosis, toxoplasmosis, and other signaling pathways to play anti-inflammatory, immune enhancement, reduce oxidative stress and other effects, so as to exert drug efficacy and alleviate sepsis. Molecular docking results showed that kaempferol and vitamin A had high affinity with key therapeutic targets involved in lipid and atherosclerotic signaling pathways, and the combination of kaempferol and JUN was the best. Conclusions: This study revealed the effective ingredients and potential mechanisms of LJJXT for treating sepsis, providing sufficient theoretical basis for its clinical treatment of sepsis and subsequent basic research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.